At a glance
- Originator Eisai Co Ltd
- Developer Abbott Laboratories; Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Peptide hydrolase inhibitors; Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer